| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PI-103 | GDSC1000 | pan-cancer | AAC | -0.06 | 0.07 |
| mRNA | PHA-665752 | GDSC1000 | pan-cancer | AAC | 0.098 | 0.07 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | -0.094 | 0.07 |
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | -0.057 | 0.07 |
| mRNA | AZD8055 | GDSC1000 | pan-cancer | AAC | -0.065 | 0.08 |
| mRNA | WZ-1-84 | GDSC1000 | pan-cancer | AAC | 0.097 | 0.08 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.069 | 0.08 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | -0.068 | 0.08 |
| mRNA | foretinib | GDSC1000 | pan-cancer | AAC | -0.062 | 0.08 |
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | 0.071 | 0.08 |